Trial Profile

Liraglutide and the management of overweight and obesity in people with schizophrenia: a pilot study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liraglutide (Primary)
Indications Obesity
Focus Adverse reactions; Therapeutic Use
Acronyms L.O.S.E Weight Version 1.0

Most Recent Events

01 Jun 2021 Results published in the Diabetes, Obesity and Metabolism
02 Apr 2019 New trial record
28 Mar 2019 According to ISRCTN record, anticipated recruitment start date is 02/07/2018 and anticipated recruitment end date is 31/07/2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com